{
  "paper_id": "PMC8122466",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122466/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Patient derived in vitro models of glioblastoma used in this study. Following surgical resection, the tissue sample is dissected and streamed into two workflows: (′) the generation of two dimensional (2D) culture of low passage patient-derived glioma stem cells (GSCs); and (″) the culture of three dimensional (3D) patient-derived glioblastoma explant organoids (GBOs). Key steps (3–5) for each workflow are mentioned and the gray-background images correspond to DIC microscopy images.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/6a55da1fbd56/ijms-22-04322-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/6a55da1fbd56/ijms-22-04322-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/6a55da1fbd56/ijms-22-04322-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/6a55da1fbd56/ijms-22-04322-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-22-04322-f001",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/6a55da1fbd56/ijms-22-04322-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8122466/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/6a55da1fbd56/ijms-22-04322-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Potential targets for glioblastoma based on literature review, current clinical management and clinical trials for glioblastoma. Note that there are only 2 (4% of the total number of targets identified in this study) targeted therapies currently approved for glioblastoma treatment in the clinic; 31 targeted therapies (62% of total) for which there is a U.S. Food & Drug Administration (FDA)- approved drug and/or are currently being evaluated in glioma/brain tumors clinical trials (https://clinicaltrials.gov); and 17 (34%) recently identified molecular targets for which there is an available drug either FDA-approved but not listed for glioblastoma or an inhibitor developed but not yet clinically approved for any medical condition.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/374d4d2619d2/ijms-22-04322-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/374d4d2619d2/ijms-22-04322-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/374d4d2619d2/ijms-22-04322-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/374d4d2619d2/ijms-22-04322-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-22-04322-f002",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/374d4d2619d2/ijms-22-04322-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8122466/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/374d4d2619d2/ijms-22-04322-g002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Drug screening pipeline in matched 2D and 3D patient-derived in vitro models for glioblastoma.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/af44ea31627e/ijms-22-04322-g003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/af44ea31627e/ijms-22-04322-g003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/af44ea31627e/ijms-22-04322-g003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/af44ea31627e/ijms-22-04322-g003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-22-04322-f003",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/af44ea31627e/ijms-22-04322-g003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8122466/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/af44ea31627e/ijms-22-04322-g003.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "Drug screening using patient-derived 2D GSC cultures. (A) (i–vii) Heatmaps of each plate representing cell viability results for G18-T cells treated with eight drug concentrations for each drug as well as negative control (StemPro Neural Stem Cell serum-free medium, NSC Medium) and vehicle control (dimethyl sulfoxide, DMSO) for each plate. The color bar of each heatmap shows bioluminescent units, an index of the number of viable cells. Red indicates low cell viability index and dark blue indicates high cell viability index. (i’–vii’) Dose vs. Response graphs for the test conditions as in (i–vii). Data are mean ± standard error of mean (SEM) for an experiment performed in quadruplicate. (B) Heatmap with hierarchical clustering representing the IC50 of each drug in FPW1 and G18-T cells. Bright red indicates low IC50 and bright blue indicates high IC50.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/0dcde1a45ae1/ijms-22-04322-g004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/0dcde1a45ae1/ijms-22-04322-g004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/0dcde1a45ae1/ijms-22-04322-g004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/0dcde1a45ae1/ijms-22-04322-g004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-22-04322-f004",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/0dcde1a45ae1/ijms-22-04322-g004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8122466/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/0dcde1a45ae1/ijms-22-04322-g004.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Figure 5.",
      "caption": "Resistance to standard of care treatment “in a dish” in 2D cultures of GSC and in GBOs. (A) Brightfield images of primary G18-T (untreated) and Stupp G18-T (temozolomide (TMZ)+radiation treated) 2D cell cultures over the 8-day treatment period. Day 0 images were taken immediately before treatment (Scale bar 300 µm). (B) Cell viability measured at the end of the protocol using CellTiter-Glo® 2.0 bioluminescence assay. (C) Brightfield images of Primary GBOs (untreated) and Stupp GBOs (TMZ+radiation treated) over the 10-day treatment period, with Day 0 images taken immediately before treatment (Scale bar 1 mm). (D) 2D area of GBOs at Day 10 for each treatment condition. All images were processed using ImageJ with consistent settings applied for all images. Data are mean ± SEM, n = 4 (B), n = 10 (D); **, p < 0.01; ns, not significant, two tailed, t-test.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/4062355c5aab/ijms-22-04322-g005.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/4062355c5aab/ijms-22-04322-g005.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/4062355c5aab/ijms-22-04322-g005.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/4062355c5aab/ijms-22-04322-g005.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-22-04322-f005",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/4062355c5aab/ijms-22-04322-g005.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8122466/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/4062355c5aab/ijms-22-04322-g005.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Figure 6.",
      "caption": "Response to second line treatment of treatment naïve and resistant glioblastoma. (A) Primary and Stupp G18-T cell line response to the addition of Vismodegib, Disulfiram, Parthenolide, Omipalisib or Costunolide. Data represent cell viability for each treatment group with the addition of each of the five selected drugs. Data are mean ± SEM for four replicates. All treatment groups were compared with their respective group (primary or Stupp) control (**** p < 0.0001, TWO-WAY ANOVA with Sidak correction for multiple comparisons). (B) GBO response to the addition of selected drugs. Brightfield images of primary GBO (untreated) and Stupp GBO (TMZ+radiation treated) with additional treatment with each selected drug over the 10-day treatment period, with Day 0 images taken before the start of the treatment. Scale bar 0.1 mm. Magnified images of primary and Stupp GBO for Control, Parthenolide and Costunolide treatment are also presented.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/9bc91cc08dcb/ijms-22-04322-g006.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/9bc91cc08dcb/ijms-22-04322-g006.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/9bc91cc08dcb/ijms-22-04322-g006.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/9bc91cc08dcb/ijms-22-04322-g006.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-22-04322-f006",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/9bc91cc08dcb/ijms-22-04322-g006.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8122466/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25a1/8122466/9bc91cc08dcb/ijms-22-04322-g006.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Aligned to this concept are the recently adopted use of low passage patient-derived GSCs and organoids (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Key steps (3–5) for each workflow are mentioned and the gray-background images correspond to DIC microscopy images.In addition to GSCs, patient-derived glioblastoma explant organoids (GBOs) have recently emerged as a promising model for studying glioblastoma tumor cells within a more physiologically relevant tumor microenvironment [9,38,47] (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Aligned to this concept are the recently adopted use of low passage patient-derived GSCs and organoids (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In addition to GSCs, patient-derived glioblastoma explant organoids (GBOs) have recently emerged as a promising model for studying glioblastoma tumor cells within a more physiologically relevant tumor microenvironment [9,38,47] (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We identified 2 molecular targets that are currently being targeted in the clinic, 31 molecular targets that are in Phase II–IV clinical trials and 17 molecular targets that have been recently discovered as new potential targets for glioblastoma (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We identified 2 molecular targets that are currently being targeted in the clinic, 31 molecular targets that are in Phase II–IV clinical trials and 17 molecular targets that have been recently discovered as new potential targets for glioblastoma (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To take advantage of each of the models and maximize throughput, speed and scalability of the drug-response assay while simultaneously overcoming their inherent limitations, we developed a new drug screening pipeline that can deliver rapid results within a clinically relevant time frame (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "To take advantage of each of the models and maximize throughput, speed and scalability of the drug-response assay while simultaneously overcoming their inherent limitations, we developed a new drug screening pipeline that can deliver rapid results within a clinically relevant time frame (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For three (Epacadostat, Plerixafor and Cetuximab) of these 16 drugs, cell viability was not altered, whereas, for the remaining 13 drugs (Veliparib, Selumetinib, Crizotinib, S3I-201, Cilengitide trifluoroacetate, Pexidartinib, Ivosidenib, CID 1375060, Tazemetostat, Indoximod, Talampanel, JR-AB2-001 and Temozolomide), it was reduced only at the highest drug concentration (500 µM), an effect that was attributed to the presence of DMSO as a similar pattern was observed with DMSO-only control (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Eight drugs [Selumertinib, Dasatinib and HA14-1 (Figure 4A(i,i’)); AZD8055, Disulfiram and Omipalisib (Figure 4A(iii,iii’)); Gilteritinib (Figure 4A(v,v’)); and Trichostatin A (Figure 4A(vi,vi’))] were observed to reduce GSC viability at 0.1 µM concentration.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This was further revealed in the dose vs. response graphs, where the cell viability of G18-T cells started to decline from 0.1 µM concentration and reached minimal cell viability at approximately 100 µM concentration (Figure 4A(i’,iii’,v’,vi’)).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The remaining 41 drugs generated a moderate response against G18-T tumor cells with the ability to reduce cell viability in G18-T tumor cells at the three highest concentrations (50, 100 and 500 µM), as evident in both the heatmaps and the dose vs. response curves (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "To compare drug responses across patients, we performed IC50 calculations for each drug in both of the GSC lines using non-linear regression analysis to identify groups of compounds that were either effective in reducing cell viability in one or both patient-derived GSC lines (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "From the heatmap representation, we identified three different group of drugs based on their differential effect on cell viability of the two patient-derived cell lines analyzed (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The first group contained 29 drugs that had an inhibitory effect on cell viability of both cell lines with IC50s in the range of 0.1–250 µM (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The second group contained 18 drugs that exhibited little to no effect on either cell line, with an IC50 range of 250–500 µM (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Finally, the third group exhibited a selective effect either on G18-T or FPW1 patient-derived GSC lines with 13 drugs having an inhibitory effect on G18-T cells only and 5 drugs having an inhibitory effect on FPW1 cells only (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Of the drugs which selectively targeted the G18-T cells, five drugs presented very strong effects on GSC viability (IC50 in the range 50 µM): Vismodegib, Disulfiram, Parthenolide, Omipalisib and Costunolide (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We also found that TMZ, which is the standard treatment for glioblastoma, did not alter G18-T cell viability (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When we compared the IC50 of TMZ in G18-T and FPW1 cells, we found that TMZ had a selective inhibitory effect on FPW1 cells (Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Images were taken using an InCell Analyser 2200 high-content microscope every 2 days to measure changes in cell confluency of 2D GSC cultures (Figure 5A,B) and in size of GBOs (Figure 5C,D).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "From the images of 2D cultures (Figure 5A), there was no significant reduction in cell viability associated with the treatment with TMZ+radiation.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "However, we observed a reduction in the growth rate and cell viability of Stupp G18-T cells when compared to primary G18-T cells (Figure 5A,B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Data are mean ± SEM, n = 4 (B), n = 10 (D); **, p < 0.01; ns, not significant, two tailed, t-test.A similar assessment of the representative images from each treatment group of GBOs (Figure 5C,D) revealed no observable effect of the Stupp protocol on GBOs at any of the timepoints to the end of treatment (Day 10) or in comparison to the primary GBOs.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Response of Stupp Treated G18-T Cell Line and GBO to Selected Drugs\nGBOs and G18-T 2D cell cultures that had previously been exposed to either the control or Stupp conditions, were treated with 50 µM of Vismodegib, Disulfiram, Parthenolide, Omipalisib or Costunolide (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "This drug concentration was well below the IC50 value determined for each drug in the G18-T cell line (as shown in Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "It is evident that all five drugs were effective in reducing cell viability, to varying extents, both primary and Stupp resistant G18-T cells (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In contrast primary and Stupp GBOs treated with Vismodegib or Disulfiram showed no clear response, although the edges of the GBOs seemed to be altered slightly compared to the control primary GBO (Figure 6B), suggesting that these treatments were ineffective in killing both primary and Stupp resistant GBOs.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Omipalisib had no effect on the GBOs as there were changes neither in primary or Stupp GBO (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Parthenolide and Costunolide were the only drugs that clearly impacted GBOs, with Parthenolide causing dissociation of the primary GBO into fragments (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "However, Parthenolide had no effect on Stupp treated GBOs (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Costunolide appeared to have an impact on both primary and Stupp GBOs as it caused the dissociation of primary GBO tissue and affected the edge morphology in Stupp GBOs (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "These alterations seemed to occur early after treatment and became evident from Day 3 (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Images were taken using an InCell Analyser 2200 high-content microscope every 2 days to measure changes in cell confluency of 2D GSC cultures (Figure 5A,B) and in size of GBOs (Figure 5C,D).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "From the images of 2D cultures (Figure 5A), there was no significant reduction in cell viability associated with the treatment with TMZ+radiation.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "However, we observed a reduction in the growth rate and cell viability of Stupp G18-T cells when compared to primary G18-T cells (Figure 5A,B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Data are mean ± SEM, n = 4 (B), n = 10 (D); **, p < 0.01; ns, not significant, two tailed, t-test.A similar assessment of the representative images from each treatment group of GBOs (Figure 5C,D) revealed no observable effect of the Stupp protocol on GBOs at any of the timepoints to the end of treatment (Day 10) or in comparison to the primary GBOs.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Images were taken using an InCell Analyser 2200 high-content microscope every 2 days to measure changes in cell confluency of 2D GSC cultures (Figure 5A,B) and in size of GBOs (Figure 5C,D).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "From the images of 2D cultures (Figure 5A), there was no significant reduction in cell viability associated with the treatment with TMZ+radiation.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "However, we observed a reduction in the growth rate and cell viability of Stupp G18-T cells when compared to primary G18-T cells (Figure 5A,B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "A similar assessment of the representative images from each treatment group of GBOs (Figure 5C,D) revealed no observable effect of the Stupp protocol on GBOs at any of the timepoints to the end of treatment (Day 10) or in comparison to the primary GBOs.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Response of Stupp Treated G18-T Cell Line and GBO to Selected Drugs\nGBOs and G18-T 2D cell cultures that had previously been exposed to either the control or Stupp conditions, were treated with 50 µM of Vismodegib, Disulfiram, Parthenolide, Omipalisib or Costunolide (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "This drug concentration was well below the IC50 value determined for each drug in the G18-T cell line (as shown in Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "It is evident that all five drugs were effective in reducing cell viability, to varying extents, both primary and Stupp resistant G18-T cells (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In contrast primary and Stupp GBOs treated with Vismodegib or Disulfiram showed no clear response, although the edges of the GBOs seemed to be altered slightly compared to the control primary GBO (Figure 6B), suggesting that these treatments were ineffective in killing both primary and Stupp resistant GBOs.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Omipalisib had no effect on the GBOs as there were changes neither in primary or Stupp GBO (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Parthenolide and Costunolide were the only drugs that clearly impacted GBOs, with Parthenolide causing dissociation of the primary GBO into fragments (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "However, Parthenolide had no effect on Stupp treated GBOs (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Costunolide appeared to have an impact on both primary and Stupp GBOs as it caused the dissociation of primary GBO tissue and affected the edge morphology in Stupp GBOs (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "These alterations seemed to occur early after treatment and became evident from Day 3 (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "GBOs and G18-T 2D cell cultures that had previously been exposed to either the control or Stupp conditions, were treated with 50 µM of Vismodegib, Disulfiram, Parthenolide, Omipalisib or Costunolide (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "This drug concentration was well below the IC50 value determined for each drug in the G18-T cell line (as shown in Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "It is evident that all five drugs were effective in reducing cell viability, to varying extents, both primary and Stupp resistant G18-T cells (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In contrast primary and Stupp GBOs treated with Vismodegib or Disulfiram showed no clear response, although the edges of the GBOs seemed to be altered slightly compared to the control primary GBO (Figure 6B), suggesting that these treatments were ineffective in killing both primary and Stupp resistant GBOs.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Omipalisib had no effect on the GBOs as there were changes neither in primary or Stupp GBO (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Parthenolide and Costunolide were the only drugs that clearly impacted GBOs, with Parthenolide causing dissociation of the primary GBO into fragments (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "However, Parthenolide had no effect on Stupp treated GBOs (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Costunolide appeared to have an impact on both primary and Stupp GBOs as it caused the dissociation of primary GBO tissue and affected the edge morphology in Stupp GBOs (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "These alterations seemed to occur early after treatment and became evident from Day 3 (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Analysis of the cell line responses permitted us to categorize the drugs into three different groups based on their differential response to drug treatments (Figure 4B and Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Analysis of the cell line responses permitted us to categorize the drugs into three different groups based on their differential response to drug treatments (Figure 4B and Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Analysis of the cell line responses permitted us to categorize the drugs into three different groups based on their differential response to drug treatments (Figure 4B and Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Artwork\nAll figures were created using Adobe Illustrator 2020, except Figure 1 and Figure 3 that were created with Biorender.com (https://biorender.com/, accessed in 1 January 2021).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "All figures were created using Adobe Illustrator 2020, except Figure 1 and Figure 3 that were created with Biorender.com (https://biorender.com/, accessed in 1 January 2021).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 6,
    "claims_count": 64,
    "images_downloaded": 6,
    "tables_filtered": 9
  }
}